SeltaSquare

1. 
2. 

• 게시판 리스트 옵션
  • 검색

Through the use of digital technologies, pharmaceutical companies can significantly improve the efficiency, speed, and quality of pharmacovigilance programs. In addition, pharmaceutical companies require new digital infrastructure capable of collecting and integrating patient health data at scale while maintaining patient consent.

   - The use of AI and supercomputing in pharmacovigilance to enhance medical drug discovery and design can improve the overall pharmacovigilance landscape by supporting the development of personalized and preventive medicine.

   - Quantum computing — demonstrated quantum utility, defined as quantum systems outperforming conventional processors of the same size, weight, and power in comparable environments — may support the development of new drug substances and pharmacovigilance solutions.

   - Post-marketing drug safety monitoring — initiatives adopted by the U.S. FDA: The FDA operates numerous initiatives that enable manufacturers, healthcare professionals, and consumers to report issues related to approved drugs. When the FDA receives reports of drug-related concerns, it may add warnings regarding dosage or usage information, and in more serious cases, take additional regulatory actions. These initiatives can help strengthen pharmacovigilance systems for drug safety.